Kymriah to be affordable to eligible patients in the UK

11:04 EST 6 Feb 2019 | BioPharma-Reporter

NICE recommends CAR T-cell treatment Kymirah to be on the Cancer Drugs Fund benefitting adult patients with lymphoma, despite previous negative appraisals.

Original Article: Kymriah to be affordable to eligible patients in the UK

More From BioPortfolio on "Kymriah to be affordable to eligible patients in the UK"